Lactosaminated N-Succinyl-chitosan: Preparation and Biodistribution into the Intestine, Bone, Lymph Nodes and Male Genital Organs after I.v. Administration

  • 발행 : 2003.10.01

초록

Reductive amination of N-succinyl-chitosan (1) and lactose using sodium cyanoborohydride in 1/15 M phosphate buffer (pH 6.0) for 6 d was suitable for the preparation of lactosaminated N-succinyl-chitosan (2). At 8, 24 and 48 h after i.v. administration of fluorescently labeled 1 (1') or 2 (2'), Peyer's patch, mesenteric lymph nodes, testes, prostate, preputial grand, intestine (small intestine plus cecum), femoral muscle, backbone and peritoneum were taken. Peyer's patch and mesenteric lymph nodes were put together as lymph nodes. Over 10% of dose/g tissue was distributed to the prostate and lymph nodes at 48 h post-administration in both l' and 2'.2' was easily distributed into not only the liver but also prostate, intestine, preputial gland and lymph nodes. Although galactose receptors are known to exist not only on the liver parenchymal cells but also on prostate and testes, the selective distribution of 2' into the prostate and the testes were not observed clearly. This study suggested that 1 and 2 should have possibilities for both the prevention and cure of lymph node metastasis as drug carriers.

키워드

참고문헌

  1. Drug Dev. Ind. Pharm. v.24 O.Felt;P.Buri;R.Gurny https://doi.org/10.3109/03639049809089942
  2. Biomaterials v.21 Y.Kato;H.Onishi;Y.Machida https://doi.org/10.1016/S0142-9612(00)00044-2
  3. J. Control. Release v.70 Y.Kato;H.Onishi;Y.Machida https://doi.org/10.1016/S0168-3659(00)00356-4
  4. Biochim. Biophys. Acta v.541 E.Regoeczi;M.T.Debanne;M.W.C.Hatton;A.Koj https://doi.org/10.1016/0304-4165(78)90196-4
  5. Ann. Rev. Biochem. v.51 G.Ashwell;J.Harford https://doi.org/10.1146/annurev.bi.51.070182.002531
  6. The Prostate v.43 A.L.Kierszenbaum;E.Rivkin;P.L.Chang;L.L.Tres;C.A.Olsson https://doi.org/10.1002/(SICI)1097-0045(20000515)43:3<175::AID-PROS3>3.0.CO;2-B
  7. Anal. Chem. v.24 L.H.Koehler https://doi.org/10.1021/ac60070a014
  8. Carbohydr. Res. v.337 Y.Kato;H.Onishi;Y.Machida https://doi.org/10.1016/S0008-6215(02)00021-6
  9. J. Am. Chem. Soc. v.93 R.F.Borch;M.D.Bernstein;H.D.Durst https://doi.org/10.1021/ja00741a013
  10. Arch. Biochem. Biophys. v.181 B.A.Schwartz;G.R.Gray https://doi.org/10.1016/0003-9861(77)90261-2
  11. Biol. Pharm. Bull. v.22 K.Kamiyama;H.Onishi;Y.Machida https://doi.org/10.1248/bpb.22.179
  12. Crit. Rev. Ther. Drug Carrier Syst. v.1 H.Sezaki;M.Hashida
  13. Biochem. Pharmacol. v.53 R.I.Mahato;S.Takemura;K.Akamatsu;M.Nishikawa;Y.Takakura;M.Hashida https://doi.org/10.1016/S0006-2952(96)00880-5
  14. FEBS Lett. v.146 L.Fiume;C.Busi;A.Mattioli https://doi.org/10.1016/0014-5793(82)80701-1
  15. FEBS Lett. v.129 L.Fiume;C.Busi;A.Mattioli;P.G.Balboni;G. Barbanti-Brodano https://doi.org/10.1016/0014-5793(81)80179-2
  16. J. Pharm. Pharmacol. v.54 Y.Kato;H.Onishi;Y.Machida https://doi.org/10.1211/0022357021778646
  17. Biomaterials v.15 G.Peluso;O.Petillo;M.Ranieri;M.Santin;L.Ambrosio;D.Calabro;B.Avallone;G.Balsamo https://doi.org/10.1016/0142-9612(94)90272-0
  18. E.X.S v.87 S.Tokura;H.Tamura;I.Azuma